Recent Progress in the Development of Novel Mycobacterium Cell Wall Inhibitor to Combat Drug-Resistant Tuberculosis

Tafere Mulaw Belete

Department of Pharmacology, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.

ABSTRACT: Despite decades of research in drug development against TB, it is still the leading cause of death due to infectious diseases. The long treatment duration, patient noncompliance coupled with the ability of the tuberculosis bacilli to resist the current drugs increases multidrug-resistant tuberculosis that exacerbates the situation. Identification of novel drug targets is important for the advancement of drug development against Mycobacterium tuberculosis. The development of an effective treatment course that could help us eradicate TB. Hence, we require drugs that could eliminate the bacteria and shorten the treatment duration. This review briefly describes the available data on the peptidoglycan component structural characterization, identification of the metabolic pathway, and the key enzymes involved in the peptidoglycan synthesis, like N-Acetylg glucosamine-1-phosphate uridylytransferase, mur enzyme, alanine racemase as well as their inhibition. Besides, this paper also provides studies on mycolic acid and arabinogalactan synthesis and the transport mechanisms that show considerable promise as new targets to develop a new product with their inhibitor.

KEYWORDS: Tuberculosis drugs, drug regimens, Mycobacterium tuberculosis, drug discovery

BACKGROUND

Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB), is an intracellular pathogen. WHO reported 10 million people developed active TB in 2019 and 1.4 million deaths; of these, 208,000 deaths occurred among people co-infected with HIV. TB is now the leading killer from a single infectious agent.1,2 The steady rise in drug resistance has added an ominous new dimension to this global health crisis with an estimated 465,000 cases of multidrug-resistant (MDR) TB, defined as TB that is resistant to isoniazid and rifampicin, with or without resistance to other first-line anti-tubercularcher drugs. Of these cases, 6.2% had extensively drug-resistant (XDR) TB that is resistant to INH and RIF in addition to any fluoroquinolones and injectable second-line drugs like kanamycin, amikacin, or capreomycin.3

Treatment of TB caused by strains resistant to at least isoniazid and rifampicin requires additional drugs and is often less effective and less tolerated.4 Additionally, treatment of MDR-TB is more expensive than the standard treatment outcomes are several times worse with a high mortality rate (50%-80%) within 4 months of diagnosis, and patients with MDR-TB have a high risk of relapse after treatment completion. TB treatments caused by an MDR strain require 2years of treatment that is too expensive with a success rate of 52% for MDR-TB and 28% for extensively drug-resistant TB (XDR-TB).5,6 Prolonged management with severe adverse effects reduces the physical and mental endurance of the patient during treatment. Such a situation facilitates the microbe to develop resistance and promote relapse among patients.

This effect makes many research companies to develop a new anti-tuberculosis drug that can effectively cure both the MDR and XDR tuberculosis, reduce treatment duration, and increase patient compliance. Therefore, it is important to develop new anti-tuberculosis drugs that can inhibit both actively multiplying bacilli and a non-growing persistent population of MTB to prevent reactivation of the infection.6,7

Over the past 50 years 2 drugs approved by the Food and Drug Administration (FDA) for the treatment of MDR-TB. Bedaquiline is the first drug approved for the treatment of multidrug-resistant TB in 2012 and pretomanid approved in 2019 as part of a 3-drug regimen (bedaquiline, pretomanid, and linezolid (BPaL)) for the management of drug-resistant TB. Delamanid is another important nitroimidazole compound approved by EMA for the treatment of MDR-TB.7,8 This review briefly describes data on the mycolic acid, peptidoglycan (PG), arabinogalactan, and the key enzymes involved in these cell wall component synthesis, as well as their inhibition. This review also provides inspiring target-based approaches that are used to develop an effective inhibitor against selected enzymes from MTB.

HISTORY OF DEVELOPMENT OF TUBERCULOSIS CHEMOTHERAPY

Streptomycin was the first antibiotic isolated in 1943 with significant activity against MTB, thereby providing hope for TB management. Effective TB chemotherapy began in 1952. MTB has developed resistance to different drugs minimizing both treatment and control.9 Between 1940 and 1980, several drugs
have been developed like Isoniazid, p-Aminosalicylic acid, Ethambutol, Rifampicin, and Ofloxacin. The discovery of Rifampicin in the 1960s with a new mechanism shortened treatment duration to 9 months. When pyrazinamide was included in the treatment regimen, the management duration decreased to 6 months. Nowadays, TB management has 4 first-line drugs: Isoniazid, Pyrazinamide, Rifampin, and Ethambutol for the first 2 months followed by Isoniazid, and Rifampin for the next 4 months. Antimycobacterial treatment success rates were 85%, and between 2000 and 2018, 58 million lives were saved. The second-line drugs used for the management of MDR-TB include fluoroquinolones (moxifloxacin, levofloxacin, ofloxacin), aminoglycosides (kanamycin, amikacin), capreomycin, cycloserine, para-aminosalicylic acid, and thioamides (ethionamide, prothionamide) as shown in Table 1. Suitable drugs regime are chosen based on efficacy, susceptibility, safety, and cost. The treatment duration of the intensive phase is 6 months when an injectable drug is added to the regime. The continuation phase without the injectable drug prolongs until 18 months after culture conversion. These drugs require a longer duration of treatment than first-line drugs resulting in toxic side effects and loss of adherence. As such, it is needed to develop new drugs that could solve the current challenges associated with the treatment of TB.

The Search for Novel Drugs and the Era of Target-Based Approaches

The problem of multidrug resistance and persistent infection will be solved with the identification of new drugs with novel modes of action. The target-based screening was rendered possible by advances in the genomics and molecular genetics of mycobacteria enabled the identification, functional characterization, and genetic validation of potential targets. The advantage of the molecular target-based approach is compound isolated as inhibitors modified to improve effectiveness and selectivity while decreasing side effects. Because of their mycobacterial-specific metabolic processes, several cell wall synthetic enzymes appeared to be promising candidates agents. Most candidates recently identified and progressed to trials identified through high-throughput screening followed by a drug-to-target approach (eg, bedaquiline and PBTZ169); however, target-based approaches are extensively used in TB drug discovery programs. Now a day, several in silico approaches proposed novel compounds as promising anti-TB agents. Ideal targets for TB drug discovery programs are proteins involved in crucial pathways of MTB that are either absent in humans or have low sequence identity to human homologs. Genomic and system biology studies are vital for novel target discovery and validation to increase the probability of successful drug discovery.

Cell Wall Synthesis Inhibitor

Mycobacterial tuberculosis (MTB) cell wall is essential to the survival of microorganisms by providing inherent resistance. This intrinsic resistance is due to the presence of thick, waxy tightly packed cell walls, and drug degrading enzymes. Cell wall synthesis gives several novel targets because synthetic enzymes do not possess homolog in humans. The current first- and second-line drugs inhibit enzymes involved in cell wall synthesis. Resistance to these drugs develops with mutations in the target enzymes or the activation pathways of the drugs, paving the way for new resistant strains. Resistance against these drugs makes the development of new drugs against the MTB cell wall. The MTB cell wall has 3 layers: PG, mycolic acids, and arabinogalactan covered with a capsule. The capsule consists of protein, polysaccharides, and several types of lipids (phthiocerol dimycocerosate, diacyl trehaloses, and phosphatidylethanolamine).

Besides these parts, different lipids components are available including non-covalently attached waxes and glycosphospholipids that act as a permeability barrier against drugs and play a key role in the survival and pathogenesis of MTB. Several enzymes facilitate the formation of mycobacterial cell wall precursors in the cytoplasm and subsequent transportation into the periplasmic space and polymerization is used as a promising target to develop a new anti-mycobacterial drug. These enzymes are mycobacterial-specific and do not have homologs in humans. The current available anti-TB drugs inhibit the synthesis of mycolic acids (Isoniazid and Ethionamide), arabinogalactan (Ethambutol), and PG (Cycloserine).

PG Synthesis Inhibitor

PG (murein) is an essential part of the cell wall found on the outside of the cell membrane of MTB that keeps the integrity of the cell by enduring pressure and maintains cell shape. PG also provides support to several cell components (proteins, teichoic acids), hence, it is essential for bacterial survival. Enzymes that involve during PG synthesis provide a promising target to develop new drugs against TB. PG has linear glycans chains of alternating N-acetylgalactosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) moiety, cross-linked by trans peptide bridges. A set of recently identified PG synthesis pathways are summarized in Figure 1.

N-Acetylgalactosamine-1-phosphate uridylyltransferase

PG synthesis starts with the conversion of fructose-6-phosphate to UDP-N-acetylgalactosamine (UDP-GlcNAc) by acetyltransferase and uridylyltransferase activity of GlmU, a bifunctional enzyme that has 2 active sites. GlmU catalyzes the acetylation of glucosamine-1-phosphate by its acetyltransferase which further nucleotide activated through uridylyltransferase, thus facilitating the synthesis of UDP-GlcNAc that is the starting material for PG synthesis. The similarity of the GlmU uridylyltransferase with human analog makes this enzyme, not a potential target. But, the lack of GlcN-1-P in humans makes the acetyltransferase domain the most promising drug target to develop a new anti-TB. Currently,
Table 1. Clinically important antitubercular drugs and their mechanism of resistance.

| DRUG NAME (YEAR OF DEVELOPMENT) | MECHANISM OF ACTION | MECHANISM OF RESISTANCE | ADVERSE EFFECT | REFERENCES |
|----------------------------------|----------------------|--------------------------|----------------|------------|
| **First-line drugs**             |                      |                          |                |            |
| Rifampicin (1957)                | Inhibit β subunit of DNA-dependent RNA polymerase | Mutation of rpoB induces a change at β-subunit of RNA polymerase, causing decrease in binding affinity | Epigastric distress, Thrombocytopenia, Leukopenia, hemolytic anemia, Menstrual disturbances | Goldstein,14 Combrink et al15 |
| Isoniazid (1951)                 | Block mycolic acid synthesis by inhibiting NADH-dependent enoyl acyl carrier protein reductase | KatG suppression causing decreased prodrug activation, and a mutation in the promoter region of InhA causing an overexpression of InhA | Hepatotoxicity, Peripheral neuritis dermatological, gastrointestinal, hypersensitivity, hematological and renal reaction | Combrink et al,15 Hsu et al16 |
| Pyrazinamide (1952)              | Not known, may disruption membrane potential | Mutations in pncA reducing conversion to active acid | Hepatotoxicity, Hyperuricaemia arthralgia, GI disturbances, Thrombocytopenia, sideroblastic anemia | Sun et al,17 Kwon et al18 |
| Ethambutol (1962)                | Arabinogalactan synthesis inhibition | Mutations in embB at codon embB306 | Optic neuritis, nausea, rashes, gastrointestinal disturbance | Saroha et al,19 Li et al20 |
| **Injectable anti-TB drugs**     |                      |                          |                |            |
| Streptomycin (1946)              | Protein synthesis inhibition | Mutations in rpsL and rrs confer binding site modulation | Itching, numbness, Ototoxicity, nephrotoxicity | Shrestha et al21 |
| Amikacin (1972)/ Kanamycin (1957) | Protein synthesis inhibition | 16S rRNA target site modulation (1400 and 1401 rrs gene) Increased drug inactivation via over expression of aminoglycoside acetyltransferase | Pain or irritation diarrhea, hearing loss, nephrotoxicity | Islam et al,22 Sowajassatakul et al23 |
| Capreomycin                     | Protein synthesis inhibition | Cross-resistance with aminoglycoside plus mutation of tlyA which decreases rRNA methyltransferase activity | Ototoxicity nephrotoxicity eosinophilia, rashes, fever, and injection site pain | Sowajassatakul et al23 |
| **Fluroquinol drugs**           |                      |                          |                |            |
| Ofloxacin (1982)                 | DNA gyrase and topoisomerase IV inhibitor | Mutations in gyrA and gyrB causing alteration to DNA Gyrase A/B binding site (later generations not always cross-resistant with first generation) and increased ABC-type efflux pump expression | Tendonitis and tendon rupture, photosensitivity, seizure, and QT prolongation Nausea, diarrhea, constipation, gas, vomiting, skin disturbances | Shi et al,24 Ginsburg et al25 |
| Levofoxacin (1992)               |                      |                          |                |            |
| Gatifloxacin                     |                      |                          |                |            |
| Moxifloxacin                     |                      |                          |                |            |
| **Second-line drugs: less effective or more toxic than first-line agents** |                      |                          |                |            |
| Ethionamide (1956)              | Mycolic acid biosynthesis inhibition | Mutations in ethA and inhA causes decreased prodrug activation and InhA overexpression (cross-resistance with Isoniazid) | Nausea and vomiting | Vilchève and Jacobs,26 Narmandakh et al27 |
| Prothionamide                    |                      |                          | Depression and hallucinations | Tan et al28 |
| Cycloserine (1955)               | Peptidoglycan synthesis inhibition | Overexpression of alrA decreasing drug efficiency | Headache, drowsiness, depression | Chen et al29 |
| Para-aminosalicylic acid (1946)  | Folic acid and iron metabolism inhibition | Mutations in the thyA causing a decrease in activated drug concentrations and folC mutations which cause binding site mutations | GI intolerance, lupuslike reactions | Minato et al30 |

(Continued)
several groups of agents have been reported as promising inhibitors of GlmU, namely, aminoquinazolines, 2-phenylbenzofurans, arylamines, arylsulfonamides, nonspecific thiol reactive agents, GlcN-6-P and GlcN-1-P GlmU analogs, and diterpenoids extracted from medicinal plants. TPSA (2-[5-(2-[4-(2-thienyl)-2-pyrimidinyl] sulfanyl)acetyl]-2-thienyl]acetic acid) with an IC₅₀ of 5.3 μM, and 2-amino-2,3-dideoxy-3-fluoro-α-d-glucopyranosyl phosphate posses excellent activity. 49,50

The Mur enzymes

After the formation of UDP-GlcNAc several Mur enzymes (MurA–F) also contribute to PG synthesis. The first Mur enzyme (MurA) transfers enolpyruvate residues from phosphoenolpyruvate to UDPGlcNAc. Later, MurB catalyzes NADPH-dependent reduction of enolpyruvate residues to D-lactate forming UDPN-acetylmuramic acid (UDP-MurNAc). The muramic acid residues in MTB contain N-acetyl and N-glycolyl derivatizations.49 Further, the synthesis of peptide part of the PG monomer unit (UDP-MurNAc-pentapeptide) is catalyzed by 4 essential Mur ligases MurC, MurD, MurE, and MurF catalyzes the addition of L-Ala, D-Glu, mDAP, and D-Ala-D-Ala to UDP-MurNAc respectively. The whole Mur enzymes are crucial for cell integrity and unique to prokaryotes that make these enzymes the most promising target to develop a new drug.51,52 In Gram-negative bacteria, fosfomycin inhibits the MurA enzyme, but mycobacterial MurA has no active site for fosfomycin attachment. Fosfomycin analogs that can inhibit MTB MurA are the most promising to develop a new drug. Several MurA inhibitors were identified using an in silico approach.53 Peptidomimetic compounds and sulfonoxan-thranilic acid derivatives posses a promising inhibitors effect against MTB MurA enzyme.54,55 MurB enzyme is essential for the viability of bacterial cells and the absence of a homolog in eukaryotic cells makes the MurB enzyme, a potential target for several inhibitors. Several MurB inhibitors were reported using structure-based drug design approaches such as Sulfadoxine, Pyrimethamine, piperazine derivatives, and Chloropicolinate Amides.56-59 As there are significant similarities in the structures of MurC and MurD/MurE and
Belete

MurF, it has a potential target to develop a drug that can block the Mur enzymes simultaneously. Glucosamine uridine analogs are inhibitors of MTB MurE enzyme.59,60

Alanine racemase inhibiter

In the cytoplasm, Alanine racemase enzymes catalyze the pyridoxal phosphate-dependent conversion of the L-alanine to D-alanine, which is essential in PG biosynthesis as shown in Figure 2. D-Cycloserine is an analog of d-alanine used as a second-line drug for TB treatment. D-Cycloserine blocks the synthesis of PG by inhibiting Alanine racemase and D-alanine-D-alanine ligase.60 Besides, D-cycloserine inhibits several PLP-dependent enzymes, inducing a severe adverse effect, and enters into the central nervous system to induce severe neurological side effects like headaches, drowsiness, depression, dizziness. So that, several studies are undertaken to develop a non-alanine analog inhibitor of Alanine racemase to minimize the off-target effects of D-cycloserine. Thiazolidinediones inhibit Alanine racemase with IC_{50} lower than 1 μM. But, their inhibition of MTB growth was not related only to Alanine racemase inhibition, since their effects could not be attenuated by providing exogenous d-alanine.51,62

Mycobacterium L, D-transpeptidase (LdtMt2) inhibiter

Overall, 80% of the peptides are cross-linked in 2 types of linkages to keep the mycobacterial cell envelope during growth and non-replicating conditions. PG structure cross-linking is catalyzed by d,d-transpeptidases (penicillin-binding proteins) and typically by the combined action of non-classical l,d-transpeptidases (Ldts) and d,d-carboxypeptidases. PG structure cross-linked mainly by 4→3 transpeptidase linkages by D,D-transpeptidase enzyme, inhibited by β-lactam antibiotic. But, there are non-classical 3→3 transpeptide linkage predominating in the PG layer of non-replicating M. tuberculosis. L,D-transpeptidase (LdtMt2) is responsible for 3 to 3 transpeptide linkages in the PG layer.63 Carbapenem antibiotics inhibit d,d-transpeptidases, l,d-transpeptidases and d,d-carboxypeptidases enzyme. LdtMt2 is essential for M. tuberculosis virulence and intrinsic resistance to β-lactam. Disruption of the ldtMt2 gene

Figure 1. Peptidoglycan synthesis pathway in M. tuberculosis.
abolishes bacterial virulence, alters colony morphology, and increased susceptibility to amoxicillin-clavulanate. Hence, LdtMt2 is considered as a potential anti-tuberculosis drug target that is inhibited by carbapenems and has attracted considerable attention as a potential anti-tuberculosis target. The next step catalyzed by Phospho-MurNAc-pentapeptide translocase (MurX/MraY, translocase I) that links the UDP-MurNAc/Glyc-L-Ala-D-Glu-meso-DAP-D-Ala to a decaprenyl phosphate (C50-P) to form lipid I. MraY is a promising target because it is vital in MTB survival. Several MraY inhibitor including Capuramycin, tunicamycin, and muraymycin D2 have promising effects to design new inhibitors. Sansanmycin and its analogs have been reported to inhibit mraY and murX.

MurG catalyzes the transfer of GlcNAc from UDP-GlcNAc to MurNAc or MurNGlyc of Lipid I to produce Lipid II. MurG activity is blocked by a lipoglycodelspipeptide antibiotic like ramoplanin and enduracidin that binds the lipid component. Then, the MurT-GatD complex and AsnB ammiate the a-carboxyl group of D-glutamate and the D-carboxyl group of meso-DAP to synthesize amidated Lipid II, respectively. These amidations are essential for PG cross-linking, and as such, the MurT-GatD complex and AsnB are the most promising targets to develop PG targeting antibiotics. The soluble UDP-MurNAc-pentapeptide translocate into the periplasmic space. The penicillin-binding proteins (PBPs) carry out transglycosylation and transpeptidation reactions to form mature PG in the periplasmic space. The MurJ Translocat Lipid II from the cytoplasm into the periplasmic space has a promising target to develop new agents including huminycin, b-lactam potentiators. But, the MurJ enzyme in MTB must be characterized and further study will help to develop a new MTB MurJ inhibitor. Ramoplanin, teixobactin, malacidin, and nisin bind Lipid II but the glycopeptides teicoplanin and vancomycin bind D-Ala-D-Ala terminus of lipid II blocking lipid II elongation. Once the lipid II is transported into the periplasmic space transglycosylase enzyme catalyzes the addition of the Lipid II to PG chains. The moenomycin blocks the transglycosylase activity of PBPs while b-lactam blocks the transpeptidase effect of PBPs. The b-lactam antibiotics have no activity against mycobacteria due to b-lactamase—BlaC that breaks down the b-lactam ring. Carbapenem could not be broken down by BlaC and combined with b-lactamase inhibitor are effective in killing Mycobacteria. Due to this effect, mero-penem plus clavulanic acid with amoxicillin (Mero/Clv/Amx) WHO endorsed the use of this regimen for the treatment of
Belete

DR-TB. Therefore, developing effective anti-tuberculosis carbapenem agent continued.33,72

Arabinogalactan synthesis inhibitor

Arabinogalactan (AG) is a heteropolysaccharide that is covalently tethered to ~10% of the muramic acid residues of PG. AG consist of galactose and arabinose that constitute ~35% of the cell wall. Both sugars exist as d-arabinofuranose (Araf) and d-galactofuranose (Galf) that are scare in nature. AG has 3 parts: the linker unit (LU), the galactan chain, and the arabinan chain.73 The d-galactofuranose posses 30 linear Galf residues linked to the rhamnosyl residue of the LU. The arabinofuranose is a branched polysaccharide with 3 tricosamer domains, each contains 23 Araf residues, linked to 8th, 10th, and 12th Galf residues of the galactan domain as shown in Figure 3.73,74

GlcNAc-1-P transferase

AG synthesis starts in the cytoplasm by forming the linker unit (LU) that connects PG to AG.

LU synthesis begins on decaprenyl-phosphate (C50-P) where GlcNAc-1-P transferase transfers GlcNAc-1-P to C50-P to form C50-P-P-GlcNAc referred to as glycolipid 1 (GL-1). GlcNAc-1-P transferase (WecA) enzyme is a promising target to develop a new drug. It is inhibited by tunicamycin and caprazamycin derivatives, such as CPZEN-45.19,75 Several In-vitro studies revealed that CPZEN-45 is active in replicating and non-replicating bacteria with potent MIC (3 µg/mL).76

Rhamnosyltransferase (WbbL)

Then rhamnosyltransferase (WbbL) catalyzes the transfer of L-rhamnose (L-Rhap) from dTDP-L-Rha to 3-position of the GlcNAc of GL-1 forming glycolipid 2 (GL-2) or the linker unit (C50-P-P-GlcNAc-L-Rha). The formation of GL-2 by using rhamnosyltransferase is a promising novel target to develop a new drug.77

Galactofuranosyltransferases

The linker unit provides an attachment site for the polymerization of the galactan chain in the cytoplasm. The bifunctional galactofuranosyltransferases (GlfT1 and GlfT2) catalyze the synthesis of the galactan chain. Initially, GlfT1 transfers Galf from UDP-Galf to the C-4 position of L-Rha, and then adds a second Galf residue to the C-5 position of the primary Galf, generating C50-P-P-GlcNAc-L-Rha-Galf1-Galf2. GlfT2 add more Galf residues to the growing galactan chain with alternating β (1→5) and β (1→6) glycosidic linkages.78 The galactan chains form C50-PP- GlcNAc-L-Rha-Galf1-Galf2. GlfT1 and GlfT2 are promising targets to develop a new drug. UDP-Galf derivatives are suitable inhibitors of these enzymes, whereby they cause premature galactan chain termination.79
Decaprenylphosphoribose-2-epimerase (DprE1 and DprE2)

Arabinofuranosyl transferase catalyzes the addition of the first Araf residues into galactan core (C50-P-P-GlcNAc-L-Rha-Galf) to form decaprenylphosphoryl-D-arabinose (DPA). DPA synthesis occurs from phospho-α-D-ribosyl-1-pyrophosphate (pRpp). The pRpp synthetase transfers pyrophosphate from ATP into C-1 of ribose-5-phosphate to produce pRpp. A decaprenyl moiety is added, catalyzed by UbiA (decaprenol-1-phosphate 5-phosphoribosyltransferase) to form decaprenol-1-monophosphate 5-phosphoribose. Then phospholipid phosphatase catalyzes C-5 dephosphorylation to form decaprenol-1-phosphoribose (DPR). Finally, DPA is formed by epimerization of the ribose C-2 hydroxyl, catalyzed by decaprenylphosphoribose-2-epimerase consisting of subunits DprE1 and DprE2.80,81 Several compounds effectively inhibit epimerase activity of MTB’s DprE1 as shown in Table 2. Nitrobenzothiazinone (BTZ-043) has a MIC of 1 ng/mL (0.23 nM) against replicating and non-replicating MTB and entered Phase1b/IIa clinical trials. BTZ-043 showed selective effect against MTB activity against both MDR and XDR-MTB strains, synergy with drug bedaquiline, and safety profile. The derivative of BTZ-043, PBTZ169 is in Phase II with MIC 0.19 ng/mL. PBTZ169 has better advantages over its predecessor including, a simple synthetic route and better pharmacodynamics.82,83 Recent studies identified the Rv3789 gene that transports DPA to the periplasmic space to donate arabinose for the synthesis of AG. Several ArafTs contribute to the assembly of arabinan into AG. AftA transfers 3 single Araf residues to the 8th, 10th, and 12th Galf residues of AG. Further α (1→5) polymerization of the arabinan domain catalyzed by EmbA and EmbB. The AftC and AftD responsible for the α (1→3) branching of the internal arabinan domain of AG. AftB catalyzes the transfer of β (1→2) Araf residues from DPA to the hexa-arabinofuranoside motif of AG. Ethambutol is the first line of anti-TB drug that inhibits AG synthesis by blocking the effect of arabinosyl transferase.84

Rhamnose synthesis inhibitor

Rhamnose is a saccharide component essential for the virulence of pathogenic bacteria. The synthesis of rhamnose is vital for mycobacterial cell growth. Inhibiting rhamnose sugar synthesis has potential drug targets because rhamnose sugar synthesis is absent in humans. l-Rhamnose synthesis comes from

---

**Table 2. Arabinogalactan biosynthesis pathway inhibitors in M. tuberculosis.**

| INHIBITORS                  | TARGET                  | MIC          | DEVELOPMENTAL PHASE (COMPANY)                  | REFERENCES |
|-----------------------------|-------------------------|--------------|-----------------------------------------------|------------|
| Caprazamycin                | WecA                    | 3 mg/mL      | Preclinical                                   | Xiong et al85 |
| CPZEN-45 (Caprazene nucleoside) | DprE1 (Covalent inhibitors) | 1.56 mg/mL   | —                                              | Xiong et al85 |
| BTZ-043 (Nitrobenzothiazinone) | DprE1 (Covalent inhibitors) | 1 ng/mL      | Phase1b/IIa((University of Munich; Hans Knoll Institute, Jena; German Center for Infection Research) | Mariandyshev et al86 |
| PBTZ169 (Mecozinone) (piperazinobenzothiazinone) | DprE1 (Covalent inhibitors) | <0.19 ng/mL | Phase II ((Innovative Medicines for Tuberculosis Foundation) | Hariguchi et al87 |
| OPC-167832 (3,4-dihydrocarbostyril derivative) | DprE1 (Covalent inhibitors) | 0.24-2 ng/mL | Phase I/II (Otsuka) | Makarov and Mikulova88 |
| TBA-7371                    | DprE1 (Covalent inhibitors) | 0.78-3.12 mM130 | Phase I (TB Alliance, Bill & Melinda Gates Medical Research Institute, Foundation for Neglected Disease Research) | Gawad and Bonde80 |
| TBI-1665                    | (Clofazimine-analog)    |              | Phase1(Institute of Materia Medica, TB Alliance, Chinese Academy of Medical Sciences & Peking Union Medical College) | Gawad and Bonde80 |
| Pyrrole-benzothiazinone     | DprE1                   | 0.16 µg/mL   | Preclinical                                   | Boeree et al89 |
| SQ109 (1,2-ethylene diamine) | MmpL3 (Ethambutol derivative) | <0.39 µg/mL | Phase II/III                                  | Furin et al90 |
| AZD-5847                    | Inhibit protein synthesis | 1.0 µg/mL    | Phase II                                     | Poos1 |
| Sutezolid                   | Inhibit protein synthesis |              | Phase 4                                      | Ntshangase et al92 |
| TBA-354                     |                         |              | Phase 1                                      | Giraud et al93 |
glucose-1-phosphate and dTTP (deoxythymidine triphosphate) by 4 different enzymes.\textsuperscript{93} Glucose-1-phosphate thymidyl transferase (RmlC), couples the glucose-1-phosphate moiety to deoxythymidine triphosphate. dTDP-6 glucose 4,6-dehydratase (RmlB), then oxidizes the 4 hydroxyls and dehydrates the 6 hydroxyls. dTDP-6-deoxy-d-xyl-4-hexulose 3,5-epimerase (RmlC), inverts the 3 and 5 hydroxyls, creating an unstable ring structure that flips. Finally, dTDP-6-deoxy-d-xyl-4-hexulose reductase (RmlD) reduces the 4 ketones to form dTDP-rhamnose. Currently, the RmlC is the best promising drug target, because RmlC is specific, unique, and does not need cofactor binding.\textsuperscript{94} Triazinoinindol-benzimidazolones inhibit RmlC enzyme.\textsuperscript{95}

Mycolic acids synthesis

Mycolic acids (MAs), 2-alkyl, 3-hydroxy long-chain fatty acids (FAs), are the hallmark of the cell envelope of Mycobacterium tuberculosis. MAs are characterized by very hydrophobic C54 to C63 fatty acids with C22 to C24 α side chain. MA in \textit{M. tuberculosis} exists as α, methoxy, and keto-mycolic acids. The α-mycolic acid is the most abundant (70%), whereas methoxy and ketone mycolic acids are the minor components (10%-15%). MA synthesis inhibitor has a promising anti-tubercular effect because it enhances the permeability and sensitivity of the organism to antibiotics.\textsuperscript{96,97} The synthesis of mycolic acids occurs in different stages as shown in Figure 4. The first is the de novo fatty acids (C16–26) that occur in the FAS-I pathway. These fatty acids help to form the α-alkyl branch (C24) or further elongated by the FAS II pathway to give fatty acids up to C56 to produce mycolic acids that are essential for the growth and survival of mycobacterium. The mammalian fatty acid synthesis is similar to the FAS I pathway, making the FAS II pathway unique to microbes.\textsuperscript{98} FAS-II pathway begins with a condensation reaction catalyzed by FabH (β-ketoacyl-ACP synthase III) using malonyl-ACP and palmitoyl-CoA to produce a β-ketoacyl-ACP intermediate. FabH enzyme links the FAS-I and FAS-II pathways. Then β-ketoacyl-AcpM is reduced by MabA (β-ketoacyl-ACP reductase), yielding β-hydroxy acyl-AcpM that is dehydrated by HadAB/BC (β-hydroxy acyl-ACP dehydratase) to produce a \textit{trans}-2-enoyl-AcpM intermediate. This is then reduced by InhA (enoyl-ACP reductase) to produce an acyl-AcpM elongated by 2 carbons. The FAS-II cycle continues with further condensation, catalyzed by KasA/B (β-ketoacyl-ACP synthase), repeating the above cycle via MabA, HadAB/BC, and InhA and continues until the acyl chain reaches C42–62, producing the saturated long-chain meromycolate.\textsuperscript{97,98}

Modification of long-chain meromycolate introduces functional groups including \textit{cis}/\textit{trans}-cyclopropanation, keto, and methoxy groups by CmaA1-2-, MmaA1-4-, and PcaA-type enzymes. The meromycolic acid chain (C42–62) is activated for condensation by generation of a meromycolyl-AMP by fatty acid adenylating enzymes (FadD32). The meromycolyl-AMP linked to α-alkyl short-chain (C22–24) in a reaction catalyzed by polyketide synthase (PKS13) to produce α-alkyl-β-keto-mycolic acid that subsequently reduced. The mycolates in the cytoplasm are converted to trehalose monomycolate (TMM), which are effluxed out through mycobacterial membrane proteins large (MmpL3). The mycolate on the translocated TMM is then coupled to AG through the mycolyltransferase Antigen 85 complex completing the mAGP assembly. Antigen 85 complex also catalyzes the synthesis of membrane unbound mycolates such as trehalose dimycolate (TDM) from TMM.\textsuperscript{99,100}

Mycolic acids targets and their inhibitors

β-Ketoacyl-acyl carrier protein synthase III (KAS III, FabH) inhibitor. FabH controls the initial step of FAS II by catalyzing the condensation of acetyl-CoA with a malonyl-acyl carrier protein (ACP) to form β-ketoacyl-ACP. The significance of FabH for bacterial viability makes it an ideal target for the development of novel bactericides.\textsuperscript{101} In the past decades, several FabH inhibitors were reported such as platsensimycin, platenacin, thiazole, and pyrazol-benzimidazole amide derivatives.\textsuperscript{102,103} Enoyl-ACP reductase (InhA) inhibitors. InhA is a clinically validated MTB target, as highlighted by the success of Isoniazid in treating patients with TB. Triclosan is one of the first InhA inhibitors identified, had a submicromolar (0.2 μM) \textit{IC}_{50} toward the target, but its antimycobacterial activity was weak with a MIC of 64 μM.\textsuperscript{102} Isoniazid and Ethionamide inhibit enoyl-ACP reductase (InhA) that is involved in the synthesis of mycolic acids that is crucial for growth and virulence. Isoniazid is prodrugs that are activated by catalase-peroxidase KatG enzyme producing reactive oxygen species that inhibit InhA and this bioactivation step is where MTB primarily develops resistance by inactivating this enzyme. Therefore, direct InhA inhibitors targeting MDR-TB would solve the risk of cross-resistance.\textsuperscript{104,105} Currently, several direct InhA inhibitors have been identified such as thiaizoles-based chemical inhibitors (GSK693), Pyrrolidinyc, Pyrrolidine, Carboxamides, Pyroles, Acetamides, Thiaizoles, and Triazole act without produg activation. Pyrrolidine and carboxamides were the best in inhibiting InhA with good bioavailability and better MIC.\textsuperscript{106} KasA and KasB inhibitor. The enzyme β-Ketoacyl ACP synthases (KasA and KasB) is a promising drug target in the mycolic acid pathway of \textit{Mycobacterium tuberculosis} (MTB).\textsuperscript{98} KasA inhibitor causes cell lysis signifying this enzyme plays a vital role in the MA pathway.\textsuperscript{107} MmpL3 inhibitors. MmpL3 export trehalose-monomycolates (TMM), precursors for trehalose-dimycolates and mycolic acids that build the mycobacterial cell wall. MmpL3 inhibitors weaken the mycobacterial cell wall and causes cell death. This highlights the promising novel target of MmpL3.\textsuperscript{108}
Several compounds were identified as MmpL3 inhibitors. SQ109 is in Phase 2b-3 trial and reported safe and effective. BM212/ BM635, NITD-304, and NITD-349 showed good preclinical safety. Polyketide synthase 13. Polyketide synthase 13 (Pks13) plays a key role in the mycolic acid synthesis and is essential in MTB survival. Pks13 condenses 2 fatty acyl chains to produce α-alkyl β-ketoesters that serve as the precursors for the synthesis of mycolic acids. Therefore, Pks13 is a promising target for a new antituberculosis drug. Currently, several Pks13 inhibitors have been reported including Cerulenin, plastensimycin, thiolactomycin, thiophene compounds, β-lactones, benzofuran derivatives (MIC 2.0 µM) and coumestan compounds. Antigen 85 complex inhibitors. Antigen 85 complex enzyme has 3 homologous (Ag85A, Ag85B, Ag85C). The Ag85C homolog catalyzes the conversion of TMMs to trehalose dimycolates (TDMs) before being attached to AG. Ag85C also helps the mycobacteria to evade the host immune response by inhibiting the formation of phagolysosomes to eradicate the infection. It has a key role in MTB virulence. The Ag85C emerged as a promising novel drug target due to its key role in forming major parts of the mycobacterial membrane. Mutation of the Ag85C gene reveals ~40% decrease in the mycolic acid amount in the cell wall. Currently, several compounds like CyC (CyCβ, CyCβ, CyCβ, CyCβ), Phosphonic acids, ebselen, Cyclipostins, and cyclophostin inhibition Ag85C causing the incorporation of MAs into the mycobacterial cell wall. FadD32 inhibitor. FadD32, a fatty acyl-AMP ligase (FAAL32) involved in the synthesis of mycolic acids. FadD32 catalyzes the conversion of fatty acid to acyl-adenylate (acyl-AMP) in the presence of adenosine triphosphate. It is conserved in all the mycobacterial species. Thus, FadD32 represents a promising target for the development of novel antituberculous drugs. Coumarin compounds showed a good antimycobacterial activity (MIC90 = 0.24-5.6 µM) against drug-susceptible and drug-resistant TB, species that provided a starting point to validate FadD32 as a promising target for the treatment of TB. But, this class of agents has short half-lives. Modification of the metabolically labile coumarin core with a 2-quinolone core achieved high antimycobacterial activity, with MIC value of 0.5 µg/mL against mycobacterial TB. Conclusion The emerging drug-resistant MTB to the current drugs makes the eradication of TB remains a global challenge. Therefore, it is urgent to develop a new drug with a novel target that does not suffer from cross-resistance with the existing drugs. It is also interesting to identify novel targets that are vital for replicating and non-replicating mycobacteria. Understanding the mechanism of action of drugs may shed light on structural elements that are needed for multi-targeting strategies. Mycobacterial cell wall synthesis inhibitor is a cornerstone for tuberculosis management. Several studies showed that enzymes are involved in cell wall synthesis and proceed to be potential drug targets in antimycobacterial drug discovery. The whole cell phenotypic screening and target-based development approaches facilitate
new groups of drug candidates being identified as mycobacterial cell wall inhibitors with excellent antimiobacterial activity. This increased a ray of hope in the discovery of new drugs that will control the problem of drug resistance. Future TB drug regimens should include inhibitors having non-canonical targets or binding different regions of the same target or blocking all alternate paths may be more effective, less prone to resistance, and may shorten therapy duration. The scientific community should try attaining a cumulative treatment outcome from different approaches, fill gaps that exist within a strategy, pursue newer treatment strategies, and continuously engage in the socio-political establishment to achieve a holistic control strategy against MTB.

Acknowledgment

I would like to acknowledge Mrs Fasika Abu for editing the paper.

Author Contributions

The author confirms sole responsibility for the design, data collection, Drafting, and critical revision of the article, and final approval of the version to be published.

ORCID iD

Tafere Mulaw Belete https://orcid.org/0000-0002-6634-5971

Data Sharing Statement

All data are provided in the manuscript or found from published papers as cited.

REFERENCES

1. Chakaya J, Khan M, Ntoumi F, et al. Global tuberculosis report 2020 – reflections on the Global TB burden, treatment and prevention efforts. Int J Tuberc Lung Dis. 2021;11:57-512.
2. van der Walt M, Keddy KH. How COVID-19 can instruct TB research: ensuring the safety of researchers exposed to infectious disease. Int J Tuberc Lung Dis. 2020;24:978-980.
3. Al-Mutairi NM, Ahmad S, Mokaddas E. Increasing prevalence of resistance to new groups of drug candidates being identified as mycobacterial cell wall inhibitors with excellent antimiobacterial activity. Eur Respir J. 2014;43:366-368.
4. Pontelli E, Ravignione MC, Migliori GB. Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives. Eur Respir Rev. 2019;28:190035.
5. Bendre AD, Peters PJ, Kumar J. Tuberculosis: past, present and future of the treatment and drug discovery research. Curr Res Pharmaceutical Drug Discovery. 2021;2:100037.
6. Rojano B, Caminero JA, Hayek M. Curving tuberculosis: current trends and future needs. Annu Global Health. 2019;85:5.
7. Park M, Sarto G, Kos OM. An update on multidrug-resistant tuberculosis. Clin Med. 2019;19:135-139.
8. Newman DJ. Antibiotics from natural sources. In: Capello-Martinez J-L, Igrejas G, eds. Antibiotics and Drug Resistance. Wiley: 2019;311-341.
9. Dwiwedi M, Giri P. Challenges in drug discovery against tuberculosis. In: Shah Y, ed. Molecular Epidemiology Study of Mycobacterium Tuberculosis Complex. Intech Open. 2021;9-30.
10. Allwood BW, Byrne A, Mephi J, Rachow A, van der Zalm MM, Schoch OD. Post-tuberculosis lung disease: clinical review of an under-recognised global challenge. Respir Rev. 2021;108:751-763.
11. Mirzaeef F, Viney K, Linh NN, et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. Eur Respir J. 2021;57:2003300.
12. Tiberi S, Scardigli A, Centris R, et al. Classifying new anti-tuberculosis drugs: rationale and future perspectives. Int J Infect Dis. 2017;56:181-184.
13. Goldstein BP. Resistance to rifampicin: a review. J Antimicrob Chemother. 2014;69:625-630.
14. Combrink M, Loots DT, du Preez I. Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin. Toxicol Lett. 2020;322:104-110.
15. Hussain F, Liu YJ, Heish P, et al. Two novel katG mutations conferring isoniazid resistance in Mycobacterium tuberculosis. Front Microbiol. 2020;11:1644.
16. Sun Q, Li X, Perer LM, Shi W, Zhang Y, Sacchettini JC. The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD. Nat Commun. 2020;11:339-347.
17. Kwon DS, Kim Y, Lee SH, et al. The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis. PLoS One. 2015;10:e0126109.
18. Saroha D, Garg D, Singh AK, Dhamija RK. Irreversible neuropathy in extremely drug-resistant tuberculosis: an unfortunate clinical conundrum. Indian J Tuberc. 2020;67:389-392.
19. Li MC, Chen R, Lin SQ, et al. Detecting ethambutol resistance in Mycobacterium tuberculosis isolates in China: a comparison between phenotypic drug susceptibility testing methods and DNA sequencing of embAB. Front Microbiol. 2020;11:781.
20. Pande R, Singh S, Tiwari S, et al. Identification of new groups of drug candidates being identified as mycobacterial cell wall inhibitors with excellent antimiobacterial activity. Front Microbiol. 2020;11:781.
21. Islam MM, Tan Y, Hameed HMA, et al. Prevalence and molecular characterization of amikacin resistance among Mycobacterium tuberculosis clinical isolates from southern China. J Glob Antimicrob Resist. 2020;22:290-295.
22. Sowajesastukad A, Pramananantana T, Chaipruck P, Phunpuch S. Molecular characterization of amikacin, kanamycin and capreomycin resistance in M/XDR-TB strains isolated in Thailand. BMC Microbiol. 2014;14:1-7.
23. Shi R, Iragaki N, Sugawara I. Overview of anti-tuberculosis (TB) drugs and their resistance mechanisms. Mini Rev Med Chem. 2007;7:1177-1185.
24. Ginsburg AS, Grosse BH, Bishai WR. Fluoroquinolones, tuberculosis, and their resistance mechanisms. Microb Sci B. 2007;2:2-4.
25. Narmandakh E, Tumenbayar O, Borolzoi T, et al. Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis in Mongolia. Antimicrob Agents Chemother. 2020;64:e00537.
26. Tan Y, Su B, Zheng H, Song Y, Wang Y, Pang Y. Molecular characterization of prothionamide-resistant Mycobacterium tuberculosis isolates in southern China. Front Microbiol. 2017;8:2358.
27. Chen J, Zhang S, Cui P, Shi W, Zhang W, Zhang Y. Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2017;72:327-329.
28. Minato Y, Thiede JM, Kordus SL, McKlveen EJ, Schiller AD. Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosaliclylic acid susceptibility and resistance. Antimicrob Agents Chemother. 2015;59:5097-5106.
29. Vilkhez C, Jacobs WR Jr. Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: genes, mutations, and causalities. Microbiol Spectr. 2014;2:4.
30. Namdarchan E, Tunenbayar O, Borolzoi T, et al. Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis in Mongolia. Antimicrob Agents Chemother. 2020;64:e01023.
31. Tan Y, Su B, Zheng H, Song Y, Wang Y, Pang Y. Molecular characterization of prothionamide-resistant Mycobacterium tuberculosis isolates in southern China. Front Microbiol. 2017;8:2358.
32. Hashemian SMR, Farhadi T, Ganijarvar M. Linezolid: a review of its properties, function, and use in critical care. Drug Des Devel Ther. 2018;12:1759-1767.
33. Jaganath D, Lamichhane G, Shah M. Carbapenems against Mycobacterium tuberculosis: a review of the evidence. Int J Tuberc Lung Dis. 2016;20:1436-1447.
34. Kumar P, Kaushik A, Bell DT, et al. Mutation in an unannotated protein confers carbapenem resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2017;61:e02324.
35. Coxon GD, Craig D, Corrales RM, Vialla E, Gannouzzi-Zaki L, Kremer L. Synthesis, antitubercular activity and mechanism of resistance of highly effective thiacetazone analogues. Parasitology. 2013;e205165.
36. Nguyen TVA, Anthony RM, Cao TTH, et al. Delamanid resistance: update and clinical management. Clin Infect Dis. 2020;71:3252-3259.
37. Lewis JM, Sloan DJ. The role of delamanid in the treatment of drug-resistant tuberculosis. Ther Clin Risk Manag. 2015;11:779-791.
38. Rifat D, Li SY, Joerguer T, et al. Mutations in oafD (B2983) as a novel determinant of resistance to pretomanid and delamanid in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2020;65:e01948.
39. Abrahams KA, Besra GS. Mycobacterial cell wall biosynthesis: a multifaceted antibiotic target. Parasitology. 2018;145:116-133.
40. Zuniga ES, Early J, Parish T. The future for early-stage tuberculosis drug discovery. Future Microbiol. 2015;10:217-229.

41. Jackson M, McNeil MR, Brennan PJ. Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis. Future Microbiol. 2013;8:855-875.

42. Maitra A, Munsu T, Healy J, et al. Cell wall peptidoglycan in Mycobacterium tuberculosis: an Achilles' heel for the TB-causing pathogen. PEMS Microbiol. 2019;43:548-568.

43. Bart SM, Burke CE, Moorey AR, Besra GS. Antibiotics and resistance: the two-sided coin of the mycobacterial cell wall. Cell Surv. 2020;6:100044.

44. Fu J, Fu H, Dieu M, et al. Identification of inhibitors targeting Mycobacterium tuberculosis cell wall biosynthesis via dynamic combinatorial chemistry. Chem Commun. 2017;53:10632-10635.

45. Ishizaki Y, Hayashi C, Ioue K, et al. Inhibition of the first step in synthesis of the mycobacterial cell wall core, catalyzed by the glucnac-1-phosphate transferase WecA, by the novel caprazamycin derivative CPZEN-45. J Biol Chem. 2013;288:4997-5003.

46. Hoagland DT, Liu J, Lee RB, Lee RE. New agents for the treatment of drug-resistant tuberculosis. Antimicrob Agents Chemother. 2021;64:4724-4730.

47. Schaechter M. Encyclopedia of Microbiology. Academic Press; 2009.

48. Patel HM, Palkar M, Karpoomath R. Exploring MDR-TB inhibitory potential of 4-Aminomethylazaoxazole as Mycobacterium tuberculosis N-Acetylglucosamine-1-Phosphate uridylytransferase (GlmU/M) inhibitors. Chem Biodiversity. 2017;20:2900237.

49. Sharma R, Khan IA. Mechanism and potential inhibitors of GlnU: a novel target for antibiotic discovery. Curr Drug Targets. 2011;12:1587-1597.

50. Li Y, Zhou Y, Ma Y, Li X. Design and synthesis of novel cell wall inhibitors of Mycobacterium tuberculosis GlnM and GlmU. Carbohydr Res. 2011;346:1714-1720.

51. Shinde Y, Ahmad I, Surana S, Patel H. The mur enzymes chink in the armour of Mycobacterium tuberculosis cell wall. Eur J Med. 2021;22:113568.

52. Eniyan K, Rani J, Ramachandran S, Bhat R, Khan IA, Baija P. Screening of antibacterial compound library identifies inhibitors of Mur enzymes in Mycobacterium tuberculosis. SLAS Dis. 2020;15:570-70.

53. Isu MA, Majumdar RS, Haidar S, Kandasamy S. Molecular and dynamic simulation of UDP-N-acetylglucosamine-1-carboxyvinyltransferase (MurA) from Mycobacterium tuberculosis using in silico approach. Inform Med Unlocked. 2018;12:56-66.

54. Kumar P, Sauyua KU, Giri R. Identification of peptidomimetic compounds as potential inhibitors against MurA enzyme of Mycobacterium tuberculosis. J Bioinform Comput Biol. 2021;19:125501.

55. Babajian B, Chaitanya M, Rajsekhar C, et al. Comprehensive structural and functional characterization of Mycobacterium tuberculosis UDP-NAG enolpyruvyl transferase (MurB-MurA) and prediction of its accurate binding affinities with inhibitors. Int J Mol Sci. 2011;13:204-216.

56. Sanad SMH, Ahmed AAM, Mekky AEM. Synthesis, in-vitro and in-silico study of novel thiozoles as potent antibacterial agents and MurB inhibitors. Arch Pharm. 2020;353:e1900309.

57. Rani J, Silla Y, Borah K, Ramachandran S, Baija P. Repurposing of FDA-approved drugs to target MurB and MurE enzymes in Mycobacterium tuberculosis. Cell Surf Biosci. 2020;10:21711-21721.

58. Konai MM, Barman S, Acharya Y, De K, Haldar J. Recent development of anti-tubercular agents to combat drug-resistant Gram-positive bacteria. In: Keshari RK, editor. Tuberculosis: a reawakening of interest. London: Academic Press; 2020:71-104.

59. Mihura S, Shukla P, Beaufay J, et al. Efficacy of β-lactam/β-lactamase inhibitor combination is linked to WhiB4-mediated changes in redox physiology of Mycobacterium tuberculosis. Life. 2017;6:e25624.

60. Alderweck LJ, Harrison J, Lloyd GS, Birch HL. The mycobacterial cell wall—peptidoglycan and Arabinogalactan. Cold Spring Harb Perspect Med. 2019;11:e038037.

61. Harrison J, Lloyd G, Joe M, et al. Lcp1 is a phosphotransferase responsible for ligating arabinogalactan to peptidoglycan in Mycobacterium tuberculosis. mBio. 2016;7:e00972.

62. Babaju KV. Liposidomycin, the first reported nucleoside antibiotic inhibitor of peptidoglycan biosynthesis translocase I: the discovery of liposidomycin and related compounds with a perspective on their application to new antibiotics. J Antibiot. 2019;72:877-889.

63. Huzsar S, Singh V, Policovici A, et al. N-acetylglucosamine-1-phosphate transferase (WecA; WeeC) as a validated drug target in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2017;61:e01130-e01137.

64. Wagstaff BA, Zorzoli A, Dorfmueller HC. NDP-amanitomycin biosynthesis and rhamnosyltransferases: building diverse glycoconjugates in nature. Biotech J. 2021;478:685-701.

65. Konstyrková Z, Sávková K, Kozon S, Mikulová K. Biosynthesis of galactan in Mycobacterium tuberculosis as a viable TB drug target? Antimicrob Agents Chemother. 2020;64:e00146-e00151.

66. Ntshangase S, Shobo A, Kruger HG, et al. The downfall of TBA-354 - a possible explanation for its neurotoxicity via mass spectrometric imaging. Front Cell Infect Microbiol. 2019;5:a021113.

67. Tran W, Kusay AS, Hawkins PME, et al. Synthetic sarsasapogenin analogues as potent Mycobacterium tuberculosis translocase I inhibitors. J Med Chem. 2014;64:17326-17345.

68. Han J, Chen J, Shao L, et al. Production of the ramoplanin activity analogue by double gene inactivation. PLoS One. 2016;11:e0154211.

69. Shaku M, Eslard C, Kana BD. Cell surface biosynthesis and remodeling pathways in mycobacteria reveal new drug targets. Front Cell Infect Microbiol. 2020;10:603382.

70. Squillag F, Ruggiero A, Berisio R. Chemistry of peptidoglycan in Mycobacterium tuberculosis life cycle: an off-the-wall balance of synthesis and degradation. Chem Eur J. 2021;27:2533-2546.

71. Konai MM, Barman S, Acharya Y, De K, Haldar J. Recent development of anti-tubercular agents to combat drug-resistant Gram-positive bacteria. In: Keshari RK, editor. Tuberculosis: a reawakening of interest. London: Academic Press; 2020:71-104.
94. Kantardjieff KA, Kim CY, Naranjo C, et al. *Mycobacterium tuberculosis* RmlC epimerase (Rv3465): a promising drug-target structure in the rhamnose pathway. *Acta Crystallogr D Biol Crystallogr*. 2004;60:895-902.

95. Sivendran S, Jones V, Sun D, et al. Identification of triazinoindol-benzimidazolones as nanomolar inhibitors of the *Mycobacterium tuberculosis* enzyme TDP-6-deoxy-d-xylo-4-hexopyranos-4-ulose 3,5-epimerase (RmlC). *Bioorg Med Chem*. 2010;18:896-908.

96. Jankute M, Cox JA, Harrison J, Besra GS. Assembly of the mycobacterial cell wall. *Annu Rev Microbiol*. 2015;69:405-423.

97. Guade R, Parish T. The genetics of cell wall biosynthesis in *Mycobacterium tuberculosis*. *Future Microbiol*. 2008;3:299-313.

98. Marrackchi H, Lanéelle MA, Daffé M. Mycolic acids: structures, biosynthesis, and beyond. *Chem Biol*. 2014;21:67-85.

99. Goins CM, Dajnowicz S, Smith MD, Parks JM, Ronning DR. Mycolyltransferase from *Mycobacterium tuberculosis* in covalent complex with tetrahydro lipstatin provides insights into antigen 85 catalysis. *J Biol Chem*. 2018;293:3651-3662.

100. Xu Z, Meshcheryakov VA, Chng SS. MmpL3 is the flipase for mycolic acids in mycobacteria. *Proc Natl Acad Sci USA*. 2017;114:7993-7998.

101. Zhao S, Xiao C, Wang J, et al. Discovery of natural FabH inhibitors using an immobilized enzyme column and their antibacterial activity against *Xanthomonas oryzae pv. oryzae*. *J Agric Food Chem*. 2020;68:14204-14211.

102. Martens E, Demain AL. Platensimycin and platencin: promising antibiotics for future application in human medicine. *J Antimicrob Chemother*. 2011;66:705-710.

103. Allahverdiyev AM, Bagirova M, Abamor ES, et al. The use of platensimycin and platencin to fight antibiotic resistance. *Infect Drug Resist*. 2013;6:99-114.

104. Ibrahim TS, Taher ES, Samir E, et al. In vitro antimycobacterial activity and physicochemical characterization of diaryl ether triclosan analogues as potential InhA reductase inhibitors. *Molecules*. 2020;25:3125.

105. Vosátková K, Krátký M, Vlčková J. Triclosan and its derivatives as antimycobacterial active agents. *Eur J Pharm Sci*. 2018;114:318-331.

106. Jain S, Sharma S, Sen DJ, Pardya SS. Enoyl-acyl carrier protein reductase (INHA): a remarkable target to exterminate tuberculosis. *Anti Infect Agents*. 2021;19:252-266.

107. Abrahams KA, Chung CW, Ghidelli-Disse S, et al. Identification of KasA as the cellular target of an anti-tubercular scaffold. *Nat Commun*. 2016;7:1-3.

108. Shao M, McNeil M, Cook GM, Lu X. MmpL3 inhibitors as antituberculosis drugs. *Eur J Med Chem*. 2020;200:112390.

109. Poce G, Consalvi S, Biava M. MmpL3 inhibitors: diverse chemical scaffolds inhibit the same target. *Mini Rev Med Chem*. 2016;16:1274-1283.

110. Malwal S, Back KH, Phan TN, et al. Lipid transporters: from bacteria, protozoa, fungi and plants, to mice and men. Preprint. Posted online May 6, 2021. *ChemRxiv*. doi:10.26434/chemrxiv.14538267.v1

111. Xu Z, Zhao S, Lv Z, et al. Benzofuran derivatives and their anti-tubercular, anti-bacterial activities. *Eur J Med Chem*. 2019;162:266-276.

112. Aggarwal A, Parai MK, Shetty N, et al. Development of a novel lead that targets M. tuberculosis polyketide synthase 13. *Cell*. 2015;170:249-259.e25.

113. Favrot L, Lajiness DH, Ronning DR. Inactivation of the *Mycobacterium tuberculosis* antigen 85 complex by covalent, allosteric inhibitors. *J Biol Chem*. 2014;289:25031-25040.

114. Pust R, Joshi A, Joshi T, et al. Identification of potent antigen 85C inhibitors of *Mycobacterium tuberculosis* via in-house lichen library and binding free energy studies Part-II. *J Med Graph Model*. 2021;103:108722.

115. Świerzko AS, Bartłomiejczyk MA, Brzostek A, et al. Mycobacterial antigen 85 complex (Ag85) as a target for ficolins and mannose-binding lectin. *Int J Med Microbiol*. 2016;306:212-221.

116. Fang C, Lee KK, Nitsuptik R, et al. Discovery of heterocyclic replacements for the coumarin core of anti-tubercular FadD32 inhibitors. *Bioorg Med Chem Lett*. 2018;28:3529-3533.

117. Cantelli CR, Dassonville-Klimpt A, Sonnet P. A review of current and promising non-tuberculous mycobacteria antibiotics. *Future Med Chem*. 2021;13:1367-1395.